See more : PT Goodyear Indonesia Tbk (GDYR.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Bod Science Limited (BOD.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bod Science Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Country Garden Services Holdings Company Limited (CGSHY) Income Statement Analysis – Financial Results
- Primemd Inc. (PRMD) Income Statement Analysis – Financial Results
- abrdn Smaller Companies Income Trust plc (ASCI.L) Income Statement Analysis – Financial Results
- MEGA International Development Co.,Ltd. (5529.TWO) Income Statement Analysis – Financial Results
- Kazera Global plc (KZG.L) Income Statement Analysis – Financial Results
Bod Science Limited (BOD.AX)
About Bod Science Limited
Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through three segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. It engages in the development and manufacture of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 875.56K | 1.72M | 3.42M | 6.58M | 5.01M | 820.22K | 852.78K | 352.88K | 0.00 | 115.61K |
| Cost of Revenue | 2.95M | 4.79M | 2.93M | 3.92M | 3.88M | 529.87K | 456.49K | 205.77K | 0.00 | 106.58K |
| Gross Profit | -2.08M | -3.08M | 498.15K | 2.66M | 1.14M | 290.35K | 396.29K | 147.11K | 0.00 | 9.02K |
| Gross Profit Ratio | -237.36% | -179.02% | 14.55% | 40.40% | 22.72% | 35.40% | 46.47% | 41.69% | 0.00% | 7.81% |
| Research & Development | 1.21M | 3.46M | 1.68M | 1.98M | 1.69M | 1.76M | 1.07M | 65.44K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 3.60M | 3.48M | 3.90M | 2.58M | 2.87M | 1.08M | 1.66M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 831.00K | 1.09M | 729.47K | 864.75K | 2.02M | 1.08M | 713.18K | 0.00 | 0.00 |
| SG&A | 2.54M | 4.43M | 4.57M | 4.63M | 3.45M | 4.89M | 2.16M | 2.38M | 0.00 | 132.82K |
| Other Expenses | 862.85K | 218.70K | 518.36K | -186.19K | -439.09K | -663.37K | -389.78K | -326.01K | 0.00 | 0.00 |
| Operating Expenses | 2.88M | 6.32M | 6.41M | 6.74M | 5.20M | 6.71M | 3.72M | 2.96M | 0.00 | 265.78K |
| Cost & Expenses | 5.84M | 11.11M | 9.33M | 10.66M | 9.08M | 7.24M | 4.18M | 3.17M | 0.00 | 372.36K |
| Interest Income | 15.04K | 15.15K | 5.14K | 19.95K | 75.96K | 70.96K | 41.05K | 0.00 | 0.00 | 323.00 |
| Interest Expense | 152.27K | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.69K | 0.00 | 0.00 |
| Depreciation & Amortization | 208.91K | 171.93K | 153.96K | 133.23K | 66.71K | 63.10K | 29.89K | 17.33K | 2.98K | 256.75K |
| EBITDA | -8.03M | -7.98M | -5.48M | -3.95M | -4.00M | -6.36M | -3.76M | -3.12M | -279.96K | 166.85K |
| EBITDA Ratio | -917.41% | -464.61% | -167.36% | -60.45% | -71.88% | -701.19% | -386.20% | -885.46% | 0.00% | -0.28% |
| Operating Income | -4.96M | -7.45M | -5.89M | -4.11M | -3.67M | -5.81M | -3.32M | -3.14M | 0.00 | -256.75K |
| Operating Income Ratio | -566.47% | -433.65% | -171.85% | -62.47% | -73.21% | -708.88% | -389.71% | -890.37% | 0.00% | -222.09% |
| Total Other Income/Expenses | -3.43M | -3.43M | -1.21M | -1.08M | -1.44M | -1.11M | -348.74K | -322.19K | 0.00 | -133.28K |
| Income Before Tax | -8.39M | -9.31M | -5.41M | -4.23M | -4.82M | -7.62M | -3.67M | -3.17M | 0.00 | -257.08K |
| Income Before Tax Ratio | -958.66% | -541.83% | -157.87% | -64.24% | -96.11% | -929.45% | -430.60% | -897.94% | 0.00% | -222.37% |
| Income Tax Expense | -1.98M | -1.36M | 17.23K | -44.92K | 316.59K | 537.42K | -41.05K | -299.32K | 0.00 | -324.00 |
| Net Income | -6.41M | -7.95M | -5.41M | -4.23M | -4.82M | -7.62M | -3.67M | -3.17M | 0.00 | -257.08K |
| Net Income Ratio | -732.44% | -462.88% | -157.87% | -64.24% | -96.11% | -929.45% | -430.60% | -897.94% | 0.00% | -222.37% |
| EPS | -0.04 | -0.06 | -0.05 | -0.04 | -0.05 | -0.11 | -0.07 | -0.09 | 0.00 | 0.00 |
| EPS Diluted | -0.04 | -0.06 | -0.05 | -0.04 | -0.05 | -0.11 | -0.07 | -0.09 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 174.27M | 141.36M | 107.34M | 100.48M | 90.38M | 66.64M | 51.83M | 34.75M | 46.03M | 0.00 |
| Weighted Avg Shares Out (Dil) | 174.27M | 141.36M | 107.34M | 100.48M | 90.38M | 66.64M | 51.83M | 34.75M | 46.03M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports